Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

T Biftu, R Sinha-Roy, P Chen, X Qian…

Index: Biftu, Tesfaye; Sinha-Roy, Ranabir; Chen, Ping; Qian, Xiaoxia; Feng, Dennis; Kuethe, Jeffrey T.; Scapin, Giovanna; Gao, Ying Duo; Yan, Youwei; Krueger, Davida; Bak, Annette; Eiermann, George; He, Jiafang; Cox, Jason; Hicks, Jacqueline; Lyons, Kathy; He, Huaibing; Salituro, Gino; Tong, Sharon; Patel, Sangita; Doss, George; Petrov, Aleksandr; Wu, Joseph; Xu, Shiyao Sherrie; Sewall, Charles; Zhang, Xiaoping; Zhang, Bei; Thornberry, Nancy A.; Weber, Ann E. Journal of Medicinal Chemistry, 2014 , vol. 57, # 8 p. 3205 - 3212

Full Text: HTML

Citation Number: 52

Abstract

In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, ...